Rapid scale-up to billions of doses requires collaborative, all-out efforts.

Preparing Pandemic Vaccine Capacity

COVID-19 therapies development, review processes geared to accelerate.

Bio/Pharma Works OT on COVID-19 Therapies

Topic

Articles

The agency published clinical data on remdesivir and information about COVID-19 treatments that have received scientific advice or informal guidance from EMA’s pandemic Task Force.

EMA Implements Transparency Measures for COVID-19 Medicines

The agency, in response to an executive order, published a list of essential medicines, medical countermeasures, and critical inputs that should be available at all times in an adequate amount to serve patient needs.

FDA Identifies Essential Medicines

Through the agreement, Takeda will handle securing the regulatory approvals before distributing the doses, while Moderna will supply the finished product.

Takeda, Moderna, and the Government of Japan to Collaborate to Distribute 50 Million COVID-19 Vaccine Doses

3P Biopharmaceuticals, and Oxford University spin-out, SpyBiotech, have signed a vaccine contract manufacturing agreement.

3P Biopharmaceuticals and SpyBiotech Sign Vaccine Manufacturing Agreement

Novartis and Molecular Partners are collaborating on the development, manufacture, and commercialization of Molecular Partners’ anti-COVID-19 DARPin program.

Novartis Collaborates with Molecular Partners on Two Anti-COVID-19 Therapies 

The UK BIA Antibody Taskforce has identified differentiated antibody combinations that will be taken into development as COVID-19 antibody therapy candidates.

UK BIA Antibody Taskforce Identifies Novel COVID-19 Antibody Therapy Candidates

The companies have signed a Statement of Intent with Gavi to make 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine available for distribution. 

Sanofi and GSK Agree to Support COVAX with 200 Million COVID-19 Vaccines Doses

Delivery will commence over the course of two months following the EUA and the government will have the ability to purchase up to 650,000 additional vials of the treatment through June 30, 2021 based on product availability and medical need.

Eli Lilly to Provide the US Government with 300,000 vials of its COVID-19 Treatment for $375 Million

The Phase III clinical trial of NVX-CoV2373 is expected to be fully enrolled in the UK and will begin in the US and Mexico by the end of November 2020.

Novavax COVID-19 Vaccine Trial Expands Enrollment

Under the partnership, Catalent has ordered visual inspection machines from Stevanato Group to install at its Bloomington, IN and Anagni, Italy facilities to support customer programs.

COVID-19 Update

Preparing Pandemic Vaccine Capacity

Bio/Pharma Works OT on COVID-19 Therapies